Mitchell Bamberger, MD
Tri-County Urology
Mitchell Bamberger, MD, MBA, FACS, is an Associate Professor of Surgery at the University of Massachusetts Medical School in Worcester and an Attending Physician at TriCounty Urology Associates and Milford Regional Medical Center. Previously, Dr. Bamberger was the Chief of Urology at Saint Vincent Hospital, a 299 bed acute care teaching hospital in Worcester. He has extensive clinical trial investigational experience with the pharmaceutical industry as well being a consultant to a number of medical device manufacturers. Dr. Bamberger is a board member of the Massachusetts Association of Practicing Urologists. He is a reviewer for the journal Urology and has authored over 50 articles, abstracts, and book chapters. (This is me - Update Profile)
| 2007 - 2008 | Attending Physician Urology Associates of Essex North Inc |
|---|---|
| 2004 - present | Attending Physician Tri-County Urology |
| 1999 - 2007 | Division Director of Urology Fallon Medical Management Co., Inc. |
| 1999 - 2007 | Chief of Urology Saint Vincent Hospital, LLC |
| 1999 - present | Associate Professor of Surgery University of Massachusetts Medical School (UMMS) |
GLG Study Groups with Mitchell Bamberger, MD(?)
GLG NewsSM Analyses by Mitchell Bamberger, MD(?)
The data gives a mixed review regarding the robotic assisted radical prostatectomy for prostate cancer. There is a clear advantage in regards to a significantly decreased risk of bleeding, post operative pain, and earlier return to normal activities. However, the data does not show a clinical...
Novel therapy for advance recurrent prostate cancer that does not rely upon traditional standard hormone therapy. This has the potential for men to continue to be sexually active while receiving treatment for advanced disease. It also opens the door to other therapeutic interventions.
The FDA has made the nasal spray formulation of DDAVP be withdrawn due to potential significant side effects of life threatening hyponatremia (low blood sodium) as well as potential seizures. I an unable to identify the data from this announcement as to why this occured. DDAVP nasal spray has been used...
This immunotherapy is based upon Insulin-like growth factor which may be expressed in prostate cancer. There is not much data on this. The study is very limited, 30 patients, and must not have received any chemotherapy prior to enrolling. The sponsor is IM Clone. I do not know...
GLG InstituteSM Seminars with Mitchell Bamberger, MD(?)
View all GLG InstituteSM Seminars in Healthcare
Request a project with Mitchell Bamberger, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms

